Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Acta Neurológica Colombiana
Print version ISSN 0120-8748On-line version ISSN 2422-4022
Abstract
CALVO-TORRES, Luis Felipe et al. Prescription patterns of riluzole in a population of patients with motor neuron disease. Acta Neurol Colomb. [online]. 2021, vol.37, n.2, pp.57-62. Epub July 04, 2021. ISSN 0120-8748. https://doi.org/10.22379/24224022367.
OBJECTIVE:
To determine the prescription pattern of riluzol and the variables associated to its use in a population of patients with motor neuron disease affiliated to the Colombian General Social Security Health System (SGSSS) in 2017.
METHOD:
Descriptive cross-sectional study. Through a systemized data base of approximately 3,5 million members to the Colombian SGSSS; patients who had been given riluzol uninterruptedly between April 1 and June 30 of 2017, were selected. Sociodemographic, pharmacological variables and comorbidities were analyzed. Defined daily dose (DDD) was estimated for 1.000 inhabitants/day and its costs.
RESULTS:
There were found 81 patients with motor neuron disease receiving riluzol, with an average age of 60,8+12,6 years. 48.1% were male. The prevalence of motor neuron disease was 29/100.000 individuals. Patients received riluzol in 50 mg tablets and the doses was estimated in 0,016 DDD for 1.000 inhabitants/day 63% were receiving medicines that reflect comorbidity or could interact with riluzol. The total cost of riluzol dispensed in 2017 was USD 85.348 and per prescribed daily dose on average was USD 2,3.
CONCLUSIONS:
The use of riluzol in patients with motor neuron disease in Colombia was carried by the recommended doses by the WHO and with a direct cost lower than reported in other countries. Studies are recommended in order to determine the effectiveness of riluzol in real-life conditions.
Keywords : Amyotrophic Lateral Sclerosis; Motor Neuron Disease; Riluzole; Drug Prescriptions; Drug Utilization; Pharmacoepidemiology (MeSH).